Two medications, different mechanisms
Semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management) and tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight management) are both injectable medications used for weight loss and blood sugar control. But they work differently at a molecular level, and that difference matters.
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which your body naturally produces after eating. This hormone stimulates insulin release, suppresses glucagon, slows gastric emptying, and acts on brain regions that regulate appetite.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone that works alongside GLP-1 in glucose regulation and appears to have additional effects on fat metabolism. This dual mechanism is why tirzepatide is sometimes called a "twincretin."
What the clinical data shows
The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that tirzepatide at its highest dose (15mg) produced an average weight loss of 22.5% of body weight over 72 weeks. The STEP 1 trial for semaglutide (2.4mg) showed an average weight loss of 14.9% over 68 weeks.
That's a meaningful difference: roughly 22% vs 15% of body weight. However, direct comparison is complicated by differences in trial design, patient populations, and the fact that not all participants reached the maximum dose. The SURPASS trials, which directly compared tirzepatide to semaglutide in diabetes patients, did show tirzepatide producing greater weight loss and better blood sugar control at comparable timeframes.
Side effect profiles
Both medications share similar gastrointestinal side effects: nausea, vomiting, diarrhea, constipation, and reduced appetite. These are largely a consequence of slowed gastric emptying and central nervous system effects that both drug classes produce.
In clinical trials, the rate of nausea was roughly similar between the two: about 40-45% for semaglutide at therapeutic doses and 25-35% for tirzepatide, depending on dose level. However, direct comparison of side effect rates between trials is unreliable because reporting methodologies differ.
Anecdotally, some patients report that tirzepatide's side effects feel somewhat different — more focused on appetite suppression and less on nausea — but individual variation is enormous. What's tolerable for one person may be difficult for another, regardless of which medication they're taking.
Dosing and administration
Both medications are administered as weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. Both use auto-injector pens that are straightforward to use.
Semaglutide (Wegovy) follows a dose escalation from 0.25mg weekly, moving up to 0.5mg, 1mg, 1.7mg, and finally 2.4mg over about 16 weeks. Semaglutide (Ozempic) follows a similar but slightly different schedule with a maximum of 2mg.
Tirzepatide (Mounjaro/Zepbound) starts at 2.5mg weekly, increasing to 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg. The escalation schedule is typically every four weeks, giving the body time to adjust at each level.
Cost and availability
As of early 2026, both medications are expensive without insurance. Semaglutide brands (Ozempic, Wegovy) typically cost $900-1,300 per month at retail. Tirzepatide brands (Mounjaro, Zepbound) are in a similar range. Insurance coverage varies significantly by plan and indication (diabetes vs weight management).
Availability has been a persistent issue for both medications. Manufacturing has struggled to keep up with demand, leading to periodic shortages. Tirzepatide has generally been easier to find in recent months, though this fluctuates by region and pharmacy.
Which one is "better"?
This is the question everyone asks, and the honest answer is: it depends on your individual situation. The clinical data suggests tirzepatide produces greater average weight loss, which is a meaningful advantage. But averages obscure wide individual variation. Some people respond exceptionally well to semaglutide and less well to tirzepatide, and vice versa.
Factors that influence which medication might be more appropriate for you include your insurance coverage, your doctor's familiarity and comfort with each drug, your tolerance for side effects, any comorbid conditions (both medications have slightly different profiles for cardiovascular and metabolic markers), and simply which one is available at your pharmacy.
What actually matters more than the medication choice
Here's the perspective that often gets lost in the semaglutide vs tirzepatide debate: the behavioral changes you make alongside either medication matter at least as much as which medication you're on. Adequate protein intake, regular physical activity, hydration, sleep, and consistent self-monitoring all significantly influence outcomes regardless of which drug is providing the pharmacological support.
The STEP and SURMOUNT trials both included lifestyle counseling for all participants. The weight loss numbers that get quoted assume patients are also making dietary and behavioral changes. The medication provides a powerful assist, but it works best as part of a comprehensive approach.
Making your decision
If you're currently deciding between semaglutide and tirzepatide, have an honest conversation with your healthcare provider about the clinical evidence, your specific health profile, insurance coverage, and practical availability. Both are effective medications with strong evidence bases. The "best" one is the one you can access, tolerate, and take consistently alongside healthy habits.
